Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States : Implication for Clinical Interpretation

[1]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[2]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[3]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[4]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[5]  K. Kayaba,et al.  Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. , 2001, American journal of epidemiology.

[6]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[7]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[8]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[9]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[10]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[11]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[12]  N Rifai,et al.  Clinical efficacy of an automated high-sensitivity C-reactive protein assay. , 1999, Clinical chemistry.

[13]  G. Lowe,et al.  Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. , 2000, Clinical chemistry.

[14]  J. Sipe,et al.  Analytical Evaluation of Particle-Enhanced Immunonephelometric Assays for C-Reactive Protein, Serum Amyloid a and Mannose-Binding Protein in Human Serum , 1998, Annals of clinical biochemistry.

[15]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[16]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[17]  N Rifai,et al.  Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. , 2001, Clinical chemistry.

[18]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[19]  Paul M. Ridker,et al.  Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death , 2002, Circulation.

[20]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.